Paragon Capital Management Inc. Purchases New Shares in Halozyme Therapeutics, Inc. $HALO

Key Points

• Paragon Capital Management opened a new stake in Halozyme, buying 18,920 shares (~$1.27M) in the fourth quarter, and institutional investors now own 97.79% of the company's stock.
• Senior insiders have been selling: COO Cortney Caudill and CEO Helen Torley each sold 20,000 shares recently, and insiders sold a total of 118,857 shares worth $8.28M over the past three months (insiders own 2.50%).
• Halozyme reported a quarterly EPS of ($0.24) vs. $1.92 expected (a large miss) while revenue rose 51.6% to $451.8M; analysts’ consensus is a “Hold” with a target price of $78.56.

Paragon Capital Management Inc. purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 18,920 shares of the biopharmaceutical company's stock, valued at approximately $1,273,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of HALO. Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the 1st quarter valued at $755,000. Acadian Asset Management LLC purchased a new stake in Halozyme Therapeutics during the 1st quarter valued at $195,000. Hsbc Holdings PLC raised its holdings in Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company's stock valued at $522,000 after buying an additional 5,448 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock valued at $140,000 after buying an additional 174 shares during the period. Finally, Baird Financial Group Inc. raised its holdings in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company's stock valued at $577,000 after buying an additional 650 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insiders Place Their Bets

In other news, COO Cortney Caudill sold 20,000 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the transaction, the chief operating officer owned 14,366 shares of the company's stock, valued at approximately $974,014.80. This represents a 58.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $49,322,187.20. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 118,857 shares of company stock worth $8,279,587 in the last three months. Corporate insiders own 2.50% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on HALO. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Weiss Ratings downgraded Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a research report on Tuesday, February 24th. TD Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Wall Street Zen downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Saturday, February 21st. Finally, Wells Fargo & Company upped their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a research report on Thursday, February 19th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $78.56.

Halozyme Therapeutics Price Performance

HALO opened at $67.82 on Monday. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The business's fifty day simple moving average is $69.32 and its 200-day simple moving average is $68.87. The company has a market capitalization of $8.03 billion, a price-to-earnings ratio of 27.24, a PEG ratio of 0.28 and a beta of 1.03.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same period in the previous year, the company posted $1.26 EPS. Halozyme Therapeutics's quarterly revenue was up 51.6% compared to the same quarter last year. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.